All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
What CEO Daniel Gold called a "ticking time bomb" apparently went off in the 102-patient phase II trial testing MEI Pharma Inc.'s histone deacetylase (HDAC) inhibitor pracinostat in combination with Vidaza (azacitidine, Celgene Corp.) against previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS), as top-line data show the pair performed no better than Vidaza by itself.